Cardiovascular disease: risk assessment and reduction, including lipid modification

Cardiovascular disease: risk assessment and reduction, including lipid modification - National Institute for Health and Care Excellence (NICE)

This guideline covers the assessment and care of adults who are at risk of or who have cardiovascular disease (CVD), such as heart disease and stroke. It aims to help healthcare professionals identify people who are at risk of cardiovascular problems including people with type 1 or type 2 diabetes, or chronic kidney disease. It describes the lifestyle changes people can make and how statins can be used to reduce their risk.

This guideline does not cover people with familial hypercholesterolaemia (FH). For guidance on FH, see NICE’s guideline on familial hypercholesterolaemia: identification and management.

In May 2023, we reviewed the evidence and made new/updated recommendations on risk assessment tools for primary prevention of CVD, cardioprotective diets, and statin treatment for primary and secondary prevention of CVD. For further details, see the update information.


Read full Guideline